Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025)
Vireo Growth (VREOF) reported Liabilities from Discontinued Operations of 89334872.0 for Q3 2025, up 1.02% on a YoY basis from 88437021.0 in Q3 2024, and little changed sequentially from 89379390.0 in Q2 2025.
Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Liabilities from Discontinued Operations data on file, last reported at 89334872.0 in Q3 2025.
- For the quarter ending Q3 2025, Liabilities from Discontinued Operations rose 1.02% year-over-year to 89334872.0; the trailing twelve-month figure through Sep 2025 stood at 89334872.0 (up 1.02% YoY), and the FY2024 full-year result was 89387203.0, up 1.2% from the prior year.
- Liabilities from Discontinued Operations was little changed at 89334872.0 in Q3 2025, from 89379390.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 89387203.0 in Q4 2024 to a low of 116803.0 in Q3 2021.
- A 5-year average of 58887381.31 and a median of 81925789.0 in 2023 frame the typical range for Liabilities from Discontinued Operations.
- Across the five-year window, Liabilities from Discontinued Operations jumped 6592.16% in 2023 and advanced 1.02% in 2025, its largest moves.
- Tracing VREOF's Liabilities from Discontinued Operations over 5 years: stood at 116803.0 in 2021, then jumped by 1029.98% to 1319847.0 in 2022, then jumped by 6592.16% to 88326323.0 in 2023, then grew by 1.2% to 89387203.0 in 2024, then retreated by 0.06% to 89334872.0 in 2025.
- Business Quant data shows VREOF's Liabilities from Discontinued Operations at 89334872.0 in Q3 2025, 89379390.0 in Q2 2025, and 89351157.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 89.33 Mn |
| Sep 30, 2025 | 89.33 Mn |
| Jun 30, 2025 | 89.38 Mn |
| Jun 30, 2025 | 89.38 Mn |
| Mar 31, 2025 | 89.35 Mn |
| Mar 31, 2025 | 89.35 Mn |
| Dec 31, 2024 | 89.39 Mn |
| Dec 31, 2024 | 89.39 Mn |
| Sep 30, 2024 | 88.44 Mn |
| Sep 30, 2024 | 88.44 Mn |
| Jun 30, 2024 | 88.41 Mn |
| Jun 30, 2024 | 88.41 Mn |
| Mar 31, 2024 | 88.37 Mn |
| Mar 31, 2024 | 88.37 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Sep 30, 2023 | 75.44 Mn |
| Sep 30, 2023 | 75.44 Mn |
| Jun 30, 2023 | 75.15 Mn |
| Jun 30, 2023 | 75.15 Mn |